Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Cholesterol Metabolite Contributes to Buildup of Atherosclerotic Plaques

By BiotechDaily International staff writers
Posted on 01 Jul 2014
A recent paper described the mechanism by which the cholesterol metabolite 27-hydroxycholesterol (27HC) contributes to the development of the fatty plaques that characterize atherosclerosis.

27HC is an abundant oxysterol metabolized by an enzyme encoded by the CYP7B1 (cytochrome P450, family 7, subfamily B, polypeptide 1) gene. This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases, which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids, and other lipids. This enzyme likely plays a minor role in total bile acid synthesis, but may also be involved in the development of atherosclerosis, neurosteroid metabolism, and sex hormone synthesis.

Investigators at the University of Texas Southwestern Medical Center (Dallas, USA) used mouse and culture models to determine how 27HC modulated lipid metabolism. Results published in the June 2014 online edition of the journal Cell Metabolism revealed that in a mouse model (apoe−/−) where 27HC was elevated due to the genetically engineered deletion of CYP7B1, development of atherosclerosis was promoted without altering lipid status while estrogen-related atheroprotection was weakened.

27HC was found to upregulate proinflammatory genes and increase adhesion via the estrogen receptor in monocytes and macrophages. In endothelial cells, 27HC was also pro-adhesive via the estrogen receptor, and in contrast to estrogen, which inhibited NF-kappaB activation, 27HC stimulated NF-kappaB activation.

"When 27HC is present, estrogen's protective effects are only observed at very high levels of the hormone," said senior author Dr. Philip W. Shaul, professor of pediatrics at the University of Texas Southwestern Medical Center. "This result may explain why hormone therapy with estrogen does not provide cardiovascular benefit in women with preexisting atherosclerosis, in which 27HC is abundant in the vascular wall. Although statins have had a dramatic impact on cardiovascular health by lowering cholesterol, we still need complementary methods to combat atherosclerosis. Targeting 27HC, either by lowering the levels of this compound or by inhibiting its actions, could potentially provide a complementary approach to preventing vascular disease."

Related Links:

University of Texas Southwestern Medical Center



Channels

Drug Discovery

view channel
Image: Researchers have attached two drugs—TRAIL and Dox—onto graphene strips. TRAIL is most effective when delivered to the external membrane of a cancer cell, while Dox is most effective when delivered to the nucleus, so the researchers designed the system to deliver the drugs sequentially, with each drug hitting a cancer cell where it will do the most damage (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Anticancer Drug Delivery System Utilizes Graphene Strip Transporters

The ongoing search by cancer researchers for targeted drug delivery systems has generated a novel approach that uses graphene strips to transport simultaneously the anticancer agents TRAIL (tumor necrosis... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Biotech Acquisition Designed to Accelerate the Development and Marketing of Immunosequencing Applications

Adaptive Biotechnologies Corp. (Seattle, WA, USA), a developer of next-generation sequencing (NGS) to profile T-cell and B-cell receptors, has acquired of Sequenta, Inc. (South San Francisco, CA, USA), which is expected to expedite and expand the use of innovative immunosequencing technology for researchers and clinicians... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.